Atypical EGFR Mutations Show Heterogeneity

A systematic analysis of patient data combined with molecular dynamics simulations and in vitro drug screens have revealed structure-function relationships that, in retrospective analyses, correctly identified drug sensitivity in patients with non-small cell lung cancer harboring atypical oncogenic EGFR mutations.